Review of the economic evaluations of hormonal therapy for patients with locally advanced prostate cancer

被引：0

作者：

Hatoum, Hind T. ^{[1
]}

Crawford, E. David ^{[2
]}

Nielsen, Sandy Kildegaard ^{[3
]}

Lin, Swu-Jane ^{[4
]}

Marshall, Dennis C. ^{[5
]}

机构：

[1] Hind T Hatoum & Co, Chicago, IL 60601 USA

[2] Univ Colorado, Aurora, CO 80045 USA

[3] European Mkt Access Ferring Int Ctr SA, CH-1162 St Prex, Switzerland

[4] Univ Illinois, Coll Pharm, Adjunct Fac, Dept Pharm Adm, Chicago, IL 60612 USA

[5] Ferring Pharmaceut Inc, Med Affairs, Parsippany, NJ 07054 USA

来源：

EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH | 2013年 / 13卷 / 02期

关键词：

androgen deprivation therapy; cost-effectiveness; degarelix; Markov simulation models; prostate cancer; quality-adjusted life years; COST-EFFECTIVENESS ANALYSIS; COMBINED ANDROGEN BLOCKADE; DRUG COVERAGE DECISIONS; REPORTED OUTCOMES; END-POINT; PERSPECTIVE; HEALTH; IMPLEMENTATION; BICALUTAMIDE; RADIOTHERAPY;

D O I：

10.1586/ERP.13.12

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Androgen deprivation therapy (ADT) is used as first-line therapy for locally advanced or metastatic prostate cancer aiming to reduce testosterone to castrate levels. The authors present an overview of the existing cost-effectiveness studies of ADT in prostate cancer. Cost-effectiveness of ADT was reviewed using a systematic search of the peer-reviewed literature, as well as research abstracts presented at various scientific and industry meetings. Most cost-effectiveness analyses of ADT reported results within the accepted societal threshold of US$50,000 cost/quality-adjusted life year needed to adopt new technology.

引用

页码：251 / 259

页数：9

共 50 条

[1] HORMONAL THERAPY FOR LOCALLY ADVANCED PROSTATE
Wirth, Manfred
[J]. INTERNATIONAL JOURNAL OF UROLOGY, 2012, 19 : 453 - 453
[2] Hormonal therapy and radiation therapy in the treatment of locally advanced prostate cancer
Sternberg, CN
[J]. MOLECULAR UROLOGY, 1999, 3 (03) : 227 - 229
[3] Evaluating the use of early hormonal therapy in patients with localised or locally advanced prostate cancer
A V Kaisary
[J]. Prostate Cancer and Prostatic Diseases, 2005, 8 : 140 - 151
[4] Evaluating the use of early hormonal therapy in patients with localised or locally advanced prostate cancer
Kaisary, AV
[J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2005, 8 (02) : 140 - 151
[5] Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer
D'Amico, AV
[J]. UROLOGY, 2002, 60 (3A) : 32 - 37
[6] Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer
D'Amico, A
[J]. UROLOGY, 2001, 58 (2A) : 78 - 82
[7] Hormonal therapy as an adjuvant to radical radiotherapy for locally advanced prostate cancer
Parker, C
Dearnaley, D
[J]. BJU INTERNATIONAL, 2003, 91 (01) : 6 - 8
[8] Neoadjuvant hormonal therapy and radical prostatectomy for locally advanced prostate cancer
Pansadoro, V
Sternberg, CN
[J]. MOLECULAR UROLOGY, 1999, 3 (03) : 271 - 274
[9] NEOADJUVANT HORMONAL DEPRIVATION IN PATIENTS WITH LOCALLY ADVANCED PROSTATE-CANCER
MACFARLANE, MT
ABIAAD, A
STEIN, A
DANELLA, J
BELLDEGRUN, A
DEKERNION, JB
[J]. JOURNAL OF UROLOGY, 1993, 150 (01): : 132 - 134
[10] Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer - Discussion
Carroll, PR
D'Amico, A
Malkowicz, SB
Gleave, ME
Bubley, GJ
[J]. UROLOGY, 2001, 58 (2A) : 82 - 82

← 1 2 3 4 5 →